The estimated Net Worth of Dennis P Wolf is at least $2.83 Milion dollars as of 23 March 2022. Mr. Wolf owns over 4,000 units of Codexis stock worth over $84,425 and over the last 21 years he sold CDXS stock worth over $2,588,048. In addition, he makes $159,989 as Independent Director at Codexis.
Dennis has made over 37 trades of the Codexis stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 4,000 units of CDXS stock worth $81,960 on 23 March 2022.
The largest trade he's ever made was selling 41,666 units of Codexis stock on 26 March 2018 worth over $464,576. On average, Dennis trades about 8,994 units every 128 days since 2003. As of 23 March 2022 he still owns at least 30,925 units of Codexis stock.
You can see the complete history of Mr. Wolf stock trades at the bottom of the page.
Dennis P. Wolf serves as Independent Director of the Company. Mr. Wolf brings to our board of directors extensive experience in financial management, corporate finance and public company corporate governance. Mr. Wolf served as Chief Financial Officer of DataStax, Inc., a private software company, from November 2013 to February 2017. Previously, Mr. Wolf served as Executive Vice President and Chief Financial Officer of Fusion-io Multisystems, a computer hardware and software company, from November 2009 to October 2013. Prior to Fusion-io, Mr. Wolf served as Executive Vice President and Chief Financial Officer of MySQL AB. Mr. Wolf has served as Chief Financial Officer of several public and private companies including Centigram Communications, Credence Systems, DataStax, Omnicell and Redback Networks. Earlier in his career he held executive positions at both Apple Computer and Sun Microsystems. Mr. Wolf has been a director and chair of the audit committee for other public companies including Quantum Corporation, Avanex Corporation, Bigband Networks, Komag, Inc., Registry Magic, Inc., Vitria Technology, Inc., Alphaeon Corporation and Exponential Interactive, Inc. He holds a B.A. from the University of Colorado and an M.B.A. from the University of Denver.
As the Independent Director of Codexis, the total compensation of Dennis Wolf at Codexis is $159,989. There are 8 executives at Codexis getting paid more, with John Nicols having the highest compensation of $3,408,030.
Dennis Wolf is 67, he's been the Independent Director of Codexis since 2007. There are 6 older and 6 younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.
Dennis's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 14 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... a John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Codexis executives and other stock owners filed with the SEC include: